Skip to main content

Table 3 The relationship between clinico-pathological stages of gastric cancer and P-gp, MRP and LRP

From: The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer

   Positive rates of MDR proteins
Stages Numbers
n(%)
P-gp*
n(%)
MRP
n(%)
LRP
n(%)
TNM stages     
T2 13 (22.0) 12 (92.3) 6 (46.2) 10 (76.9)
T3 44 (74.6) 37 (84.1) 10 (22.7) 39 (88.6)
T4 2 (3.4) 2 (100) 0 (0.0) 1 (50.0)
N0 24 (40.7) 21 (87.5) 10 (41.7) 21 (87.5)
N1 18 (30.5) 14 (77.8) 2 (11.1) 15 (83.3)
N2 15 (25.4) 14 (93.3) 3 (20.0) 12 (80.0)
N3 2 (3.4) 2 (100) 1 (50.0) 2 (100.0)
M0 57 (96.6) 49 (86.0) 16 (28.1) 49 (86.0)
M1 2 (3.4) 2 (100.0) 0 (0.0) 1 (50.0)
Clinical stages     
IB 10 (16.9) 10 (100) 6 (60.0) 9 (90.0)
II 13 (22.0) 10 (76.9) 4 (30.8) 11 (84.6)
IIIA 18 (30.5) 14 (77.8) 2 (11.1) 16 (88.9)
IIIB 14 (23.7) 13 (92.9) 3 (21.4) 12 (85.7)
IV 4 (6.8) 4 (100) 1 (25.0) 2 (50.0)
  1. * The positive rate of P-gp is correlated positively with clinical stages (r = 0.742).